Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | KDM5A | P29375 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224770 | 1.00 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1MAPTHRH2HRH1 | |
| SCHEMBL3955552 | 0.93 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1MAPTHRH2HRH1 | |
| SCHEMBL30365687 | 0.93 | ALDH1A1 (0.62) | ALDH1A1L3MBTL1MAPTHRH2HRH1 | |
| SCHEMBL10212594 | 0.92 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1MAPTHRH2HRH1 | |
| SCHEMBL10223154 | 0.85 | USP30 (0.56) | L3MBTL1KDM5AMMP2ANPEPHDAC4 | |
| SCHEMBL356346 | 0.85 | USP30 (0.56) | L3MBTL1KDM5AMMP2ANPEPHDAC4 | |
| SCHEMBL18230112 | 0.85 | USP30 (0.56) | L3MBTL1KDM5AMMP2ANPEPHDAC4 | |
| SCHEMBL358264 | 0.84 | CTSL (0.63) | ALDH1A1RAB9ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL10274561 | 0.84 | CTSL (0.63) | ALDH1A1RAB9ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL28683089 | 0.84 | SMN1; SMN2 (0.59) | ALDH1A1L3MBTL1MAPTRAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ALDH1A1 387/4885L3MBTL1 3197/4885MAPT 4355/4885 |
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | ALDH1A1 166/4885L3MBTL1 2749/4885MAPT 1870/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | ALDH1A1 301/4885L3MBTL1 2443/4885MAPT 1867/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ALDH1A1 166/4885L3MBTL1 2749/4885MAPT 1870/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ALDH1A1 166/4885L3MBTL1 2749/4885MAPT 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.